The safety and toxicity of minor cannabinoids found in plants, particularly when ingested in amounts not typically present in nature, have long been subjects of debate. Given the decades-long research ban, safety studies, toxicity assessments, and consumer reports are crucial for gaining a better understanding of these cannabinoids. For Casco Bay Hemp, patients, and consumers in the industry, such research is indispensable.

Hera BioLabs and 3Chi Delta-8 Study

Recently, a significant toxicity study was conducted by Hera BioLabs, sponsored by 3Chi, to provide additional reassurance regarding the safety of Delta-8 THC products. The study aimed to determine the tolerability of Delta-8 THC in rats, using established methods to extrapolate the effects to humans. The human equivalent doses (HED) tested were 10, 25, 50, 100, and 500 mg for a 60 kg individual. While the average Delta-8 THC dose is around 25 mg, the study tested doses up to 20 times higher.

Key Findings:

Throughout the study, no adverse impacts were observed in the rats. There were no instances of mortality, clinical signs of distress, or moribundity. While reduced activity was noted upon dosing, this returned to normal within the observation period.

Implications for the Industry:

This study adds to the growing body of evidence supporting the safety of minor cannabinoids, including Delta-8 THC. An estimated 40 million Americans tried Delta-8 products in the past year. These products are popular for their therapeutic benefits, which include anti-inflammatory properties, pain relief, sleep aid, dietary support, and chemotherapeutic assistance. Delta-8 THC is often preferred over Delta-9 THC due to its lower psychoactive effects, providing similar benefits with less mind-altering impact.


The findings from this and similar studies highlight the significant positive impact these products can have on people’s lives, demonstrating their safety and efficacy. While continued research is always valuable, we now have a solid foundation supporting the safe use of Delta-8 THC.

  • Wilson-Poe AR, Smith T, Elliott MR, Kruger DJ, Boehnke KF. Past-Year Use Prevalence of Cannabidiol, Cannabigerol, Cannabinol, and Δ8-Tetrahydrocannabinol Among US Adults. JAMA Netw Open. 2023;6(12):e2347373. doi:10.1001/jamanetworkopen.2023.47373
  • Kruger, J.S., Kruger, D.J. Delta-8-THC: Delta-9-THC’s nicer younger sibling?. J Cannabis Res 4, 4 (2022).